SNNLive interview with J.J. Finkelstein, President & CEO of RegeneRx Biopharmaceuticals, Inc. at the 4th Annual SeeThruEquity MicroCap Investor Conference 2015 in New York City, NY.

Watch the video interview.

Shareholder letter - Tuesday February 17, 2015

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

September 21, 2015
RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RGN-259

September 16, 2015
RegeneRx Announces First Patients Enrolled in Phase 2b/3 U.S. Dry Eye Clinical Trial with RGN-259

September 2, 2015
RegeneRx to Present at Rodman & Renshaw Global Investment Conference

August 12, 2015
New Publication Elaborates on TB4's Effects on Dry Eye Syndrome and Other Potential Ophthalmic Disorders

August 6, 2015
RegeneRx Provides Update on Clinical Trials in U.S., Korea and China

July 22, 2015
RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment

July 17, 2015
RegeneRx Korean Licensee Receives Government Approval to Conduct Phase 2b/3 Clinical Trial in Patients with Dry Eye Syndrome